Picture loading failed.

Anti-ERBB2 therapeutic antibody (Pre-made Coprelotamab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-119-1mg 1mg 3090
GMP-Bios-ab-119-10mg 10mg 21890
GMP-Bios-ab-119-100mg 100mg 148000
GMP-Bios-ab-119-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-ERBB2 therapeutic antibody (Pre-made Coprelotamab biosimilar,Whole mAb)
INN Name Coprelotamab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD
99% SI Structure1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC
95-98% SI Structure5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL
Year Proposed2020
Year Recommended2021
CompaniesGenor Biopharma
Conditions Approvedna
Conditions ActiveCancers
Conditions Discontinuedna
Development TechCoprelotamab is a biosimilar of Trastuzumab and Timigutuzumab with an identical Variable region. Cinrebafusp have identical V domain.